Large Cap Pharma Stock To Consider Dividend Payment, Rallies 20% In 30 Days

Large cap pharmaceuticals sector stock, Torrent Pharmaceuticals Ltd shares witnessed a decline of 0.14% in trade today even after it informed via its BSE filing about its upcoming meeting of Board of Directors on February 02, 2024 to consider financial results and interim dividend. Torrent Pharmaceuticals shares surged 20.37% in last 1-month and rose 60% in last 1-year. Check details below:

Torrent Pharmaceuticals To Consider Financial Results, Interim Dividend: As per the regulatory filing of the company dated January 12, 2024, "We would like to inform you that a meeting of the Board of Directors will be held on Friday, 02-Feb-24, inter alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and nine months ended on 31-Dec-23. The Board would also consider payment of Interim Dividend for the year 2023-24."

Torrent Pharmaceuticals Sets Record Date For Dividend: The Company has fixed Monday, 12th February, 2024 as the Record Date for taking record of the Members of the Company for the purpose of payment of Interim Dividend, if declared by the Board at their meeting scheduled to be held on Friday, 02nd February, 2024, added the BSE filing of the company.

Torrent Pharmaceuticals Stock Performance & Return: The 52-week high price of Torrent Pharmaceuticals share is Rs 2477.25 apiece and 52-week low price is Rs 1446.15 apiece, respectively. The company has a market capitalisation of Rs 83,544.89 crore. Torrent Pharmaceuticals shares gained 56% in last 2-years, soared 74% in last 3-years, and offered return of 162% in last 5-years.

Torrent Pharmaceuticals Q2 Results: The leading Indian drugmaker posted approximately 24% surge in its Q2 profit, led by robust demand in domestic market and in Brazil. It announced its consolidated net profit at Rs 3.86 billion ($46.4 million) for the quarter ended September 30, against Rs 3.12 billion an year ago. Revenue from operations soared 16.1% to Rs 26.60 billion because sales grew 18% in India and 36% in Brazil. Meanwhile, margins on earnings before interest, taxes, depreciation and amortization (EBITDA) rose to 31% from 30% an year ago.

Disclaimer:

The stock highlights the dividend and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.